Recordati S.p.A. - Recordati: lercanidipine collaboration in Japan between Tsumura and Dainippon

Press Releases

Recordati: lercanidipine collaboration in Japan between Tsumura and Dainippon

Milan, 21 December 2001

Recordati announced today that a preliminary collaboration agreement between the Japanese pharmaceutical companies Tsumura & Co., the Japanese licensee for lercanidipine, a calcium channel blocker, discovered and developed by Recordati, for the treatment of hypertension, and Dainippon Pharmaceutical Co. was signed. Under this agreement both companies are committed, within June 2002, to enter into a co-development and co-marketing contract to create the best conditions for the registration and success of lercanidipine in Japan.

The Japanese pharmaceutical market is the second largest worldwide. In Japan around 20 million people suffer from hypertension of which only 7.5 million are currently treated. The calcium channel blocker market, to which lercanidipine belongs, is worth over $ 2 billion. The two Japanese pharmaceutical companies expect to launch lercanidipine in 2005.

"We are very pleased with the agreement between our licensee Tsumura and Dainippon Pharmaceutical", declared Giovanni Recordati, Chairman and CEO. "Thanks to this collaboration the resources dedicated to a fast and effective performance of lercanidipine on the Japanese market will be strengthened".

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Portugal, Spain, Switzerland and the United States.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2001 Print Page Bookmark Page
Recordati at a glance Key Financial Data Recordati Share Press Releases 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Regulated information Shareholders’ Meetings Calendar Analyst Coverage Contacts	Press Releases Recordati: lercanidipine collaboration in Japan between Tsumura and Dainippon Milan, 21 December 2001 Recordati announced today that a preliminary collaboration agreement between the Japanese pharmaceutical companies Tsumura & Co., the Japanese licensee for lercanidipine, a calcium channel blocker, discovered and developed by Recordati, for the treatment of hypertension, and Dainippon Pharmaceutical Co. was signed. Under this agreement both companies are committed, within June 2002, to enter into a co-development and co-marketing contract to create the best conditions for the registration and success of lercanidipine in Japan. The Japanese pharmaceutical market is the second largest worldwide. In Japan around 20 million people suffer from hypertension of which only 7.5 million are currently treated. The calcium channel blocker market, to which lercanidipine belongs, is worth over $ 2 billion. The two Japanese pharmaceutical companies expect to launch lercanidipine in 2005. "We are very pleased with the agreement between our licensee Tsumura and Dainippon Pharmaceutical", declared Giovanni Recordati, Chairman and CEO. "Thanks to this collaboration the resources dedicated to a fast and effective performance of lercanidipine on the Japanese market will be strengthened". Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Portugal, Spain, Switzerland and the United States.